siRNA therapy decreases triglycerides in clients with rare disorder

.RESEARCH HIGHLIGHT.19 September 2024.

Plozasiran lessened triglyceride levels through 80% and decreased the danger of pancreatitis in individuals with persistent chylomicronemia, with or even without a genetic prognosis.